LUNA-18
- Generic Name
- LUNA-18
AstraZeneca Secures KRAS G12D Inhibitor in $419M Deal with Usynova
• AstraZeneca has licensed UA022, a novel KRAS G12D inhibitor, from Chinese biotech Usynova for $24 million upfront, with potential milestone payments reaching $395 million.
• The preclinical compound targets KRAS G12D mutations, which account for 26% of all KRAS mutations and are commonly found in pancreatic and colorectal cancers, addressing a significant unmet medical need.
• This strategic move positions AstraZeneca among select companies developing KRAS G12D inhibitors, including Mirati, Revolution Medicines, and Roche/Chugai, expanding the frontier of precision oncology.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath